International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Ondansetron for Prevention of Spinal-Induced Hypotension in Cesarean Section: A Randomized Study Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development

Dr Sarveshwar, Dr Ankur Sehgal

Resident, Department of Anaesthesia, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India

Article Information

Volume / Issue7 / 1 (January-March 2026)
Pages119-128
AccessOpen Access

Publication Timeline

  • Received22 November 2025
  • Accepted24 December 2025
  • Published

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Background: The development of pharmacological interventions for perioperative complications, particularly spinal anesthesia-induced hypotension during cesarean section, faces substantial challenges including prolonged discovery timelines, high attrition rates, and limited translation of preclinical findings to clinical efficacy. Traditional drug development approaches require extensive time and financial investment, often spanning 10-15 years from initial target identification to regulatory approval. Ondansetron, a selective serotonin 5-HT3 receptor antagonist, exemplifies successful drug repurposing for preventing hypotension in obstetric anesthesia, yet its identification for this indication emerged through clinical observation rather than systematic screening approaches. 
Aim: This article examines innovative strategies in pharmaceutical development that can accelerate therapeutic discovery and validation, with particular emphasis on high-throughput screening methodologies, computational target identification, and translational research frameworks applicable to perioperative medicine. 
Discussion: Modern drug discovery increasingly leverages high-throughput screening platforms, structure-based drug design, and pharmacogenomic approaches to identify lead compounds with optimal therapeutic profiles. These strategies enable simultaneous evaluation of thousands of molecular entities against validated biological targets, dramatically reducing initial screening phases. Target identification and validation through genomic and proteomic technologies, combined with advanced preclinical modeling systems, facilitate more accurate prediction of clinical efficacy and safety profiles. 
Impact: Implementation of these accelerated development strategies has demonstrated substantial reductions in discovery timelines and improved success rates in clinical translation, particularly for repurposed medications and precision medicine applications. 
Perspective: Future advancement requires integration of artificial intelligence-driven prediction models, patient-specific precision medicine approaches, and adaptive clinical trial designs to further optimize therapeutic development for perioperative and obstetric applications.
 

Keywords

Drug discoveryPharmaceutical developmentTranslational researchHigh-throughput screeningLead optimizationPrecision medicine

References

  1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of research and development costs. J Health Econ. 2016;47:20-33. [Google Scholar][Crossref]
  2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-716. [Google Scholar][Crossref]
  3. Klumpenhouwer SD, Mercier FJ, van der Holt B, Heesen MA. Ondansetron for prevention of hypotension after spinal anesthesia for cesarean section: a systematic review and meta-analysis. Eur J Anaesthesiol. 2022;39(2):108-118. [Google Scholar][Crossref]
  4. Ngan Kee WD. Prevention of maternal hypotension after regional anaesthesia for caesarean section. Curr Opin Anaesthesiol. 2010;23(3):304-309. [Google Scholar][Crossref]
  5. Owczuk R, Wenski W, Polak -Krzeminska A, Twardowski P, Arszulowicz R, Dylczyk-Sommer A, et al. Ondansetron given intravenously attenuates arterial blood pressure drop due to spinal anesthesia: a double-blind, placebo-controlled study. Reg Anesth Pain Med. 2008;33(4):332-339. [Google Scholar][Crossref]
  6. Morgan PJ, Halpern SH, Lam-McCulloch J. Comparison of maternal satisfaction between epidural and spinal anesthesia for elective cesarean section. Can J Anaesth. 2000;47(10):956-961. [Google Scholar][Crossref]
  7. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690. [Google Scholar][Crossref]
  8. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507-519. [Google Scholar][Crossref]
  9. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve research and development productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214. [Google Scholar][Crossref]
  10. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383):eaag1166. [Google Scholar][Crossref]
  11. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856-860. [Google Scholar][Crossref]
  12. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012;30(4):317-320. [Google Scholar][Crossref]
  13. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical research and development efficiency. Nat Rev Drug Discov. 2012;11(3):191-200. [Google Scholar][Crossref]
  14. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188-195. [Google Scholar][Crossref]
  15. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds from screening libraries. J Med Chem. 2010;53(7):2719-2740. [Google Scholar][Crossref]
  16. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26. [Google Scholar][Crossref]
  17. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475-486. [Google Scholar][Crossref]
  18. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005;10(21):1421-1433. [Google Scholar][Crossref]
  19. Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12(8):569. [Google Scholar][Crossref]
  20. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431. [Google Scholar][Crossref]
  21. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4-17. [Google Scholar][Crossref]
  22. Mullard A. New drugs cost US 2.6 billion dollars to develop. Nat Rev Drug Discov. 2014;13(12):877. [Google Scholar][Crossref]
  23. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51. [Google Scholar][Crossref]
  24. Ngan Kee WD, Khaw KS, Ng FF. Prevention of hypotension during spinal anesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. Anesthesiology. 2005;103(4):744-750. [Google Scholar][Crossref]
  25. Mercier FJ, Riley ET, Frederickson WL, Roger-Christoph S, Benhamou D, Cohen SE. Phenylephrine added to prophylactic ephedrine infusion during spinal anesthesia for elective cesarean section. Anesthesiology. 2001;95(3):668-674. [Google Scholar][Crossref]
  26. Sahoo T, SenDasgupta C, Goswami A, Hazra A. Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study. Int J Obstet Anesth. 2012;21(1):24-28. [Google Scholar][Crossref]
  27. Wang M, Zhuo L, Wang Q, Shen MK, Yu YY, Yu JJ, et al. Efficacy of prophylactic intravenous ondansetron on the prevention of hypotension during cesarean delivery: a dose-dependent study. Int J Obstet Anesth. 2014;23(4):362-368. [Google Scholar][Crossref]
  28. Marashi SM, Soltani-Omid S, Soltani Mohammadi S, Aghajani Y, Movafegh A. Comparing two different doses of intravenous ondansetron with placebo on attenuation of spinal-induced hypotension and shivering. Anesth Pain Med. 2014;4(2):e12055. [Google Scholar][Crossref]
  29. Trujillo KA, Montoya DA, Orduña V. The 5-HT3 receptor antagonist granisetron prevents maternal hypotension during cesarean delivery under spinal anesthesia. J Clin Anesth. 2020;60:43-44. [Google Scholar][Crossref]
  30. Tubog TD, Kane TD, Pugh MA. Effects of ondansetron on attenuating spinal anesthesia-induced hypotension and bradycardia in obstetric and nonobstetric subjects: a systematic review and meta-analysis. AANA J. 2017;85(2):113-122. [Google Scholar][Crossref]
  31. Zieleskiewicz L, Noel A, Duclos G, Haddam M, Delmas A, Baumstarck K, et al. Can point-of-care ultrasound predict spinal hypotension during caesarean section? A prospective observational study. Anaesthesia. 2018;73(1):15-22. [Google Scholar][Crossref]
  32. Hasanin AM, Amin SM, Agiza NA, Elsayed MK, Refaat S, Hussein HA, et al. Norepinephrine infusion for preventing postspinal anesthesia hypotension during cesarean delivery: a randomized dose-finding trial. International Journal of Medical and All Body Health Research www.allmedicaljournal.com Anesthesiology. 2019;130(1):55-62. [Google Scholar][Crossref]
  33. Habib AS. A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. Anesth Analg. 2012;114(2):377-390. [Google Scholar][Crossref]
  34. Kinsella SM, Carvalho B, Dyer RA, Fernando R, McDonnell N, Mercier FJ, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia. 2018;73(1):71-92. [Google Scholar][Crossref]
  35. Pushparani A, Booth JV. Drug development and discovery from in silico tools to clinical application. Expert Opin Drug Discov. 2020;15(9):1071-1082. [Google Scholar][Crossref]
  36. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, et al. Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 2020;19(5):353-364. [Google Scholar][Crossref]
  37. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477. [Google Scholar][Crossref]
  38. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-780. [Google Scholar][Crossref]
  39. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market 2009 -2018. JAMA. 2020;323(9):844-853. [Google Scholar][Crossref]
  40. Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495-496. [Google Scholar][Crossref]

How to Cite

Sarveshwar, & Sehgal, A. (2026). Ondansetron for Prevention of Spinal-Induced Hypotension in Cesarean Section: A Randomized Study Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development. International Journal of Medical and All Body Health Research, 7(1), 119-128. https://doi.org/10.54660/IJMBHR.2026.7.1.119-128

Sarveshwar, and Ankur Sehgal. "Ondansetron for Prevention of Spinal-Induced Hypotension in Cesarean Section: A Randomized Study Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development." International Journal of Medical and All Body Health Research, vol. 7, no. 1, 2026, pp. 119-128. https://doi.org/10.54660/IJMBHR.2026.7.1.119-128.

Sarveshwar and Sehgal, A. (2026) 'Ondansetron for Prevention of Spinal-Induced Hypotension in Cesarean Section: A Randomized Study Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development', International Journal of Medical and All Body Health Research, 7(1), pp. 119-128. doi: 10.54660/IJMBHR.2026.7.1.119-128.

Sarveshwar, Sehgal A. Ondansetron for Prevention of Spinal-Induced Hypotension in Cesarean Section: A Randomized Study Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development. International Journal of Medical and All Body Health Research. 2026;7(1):119-128. doi:10.54660/IJMBHR.2026.7.1.119-128

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASE

A newly published article may take a few days to appear on these services.